JP2019524723A5 - - Google Patents

Download PDF

Info

Publication number
JP2019524723A5
JP2019524723A5 JP2019501427A JP2019501427A JP2019524723A5 JP 2019524723 A5 JP2019524723 A5 JP 2019524723A5 JP 2019501427 A JP2019501427 A JP 2019501427A JP 2019501427 A JP2019501427 A JP 2019501427A JP 2019524723 A5 JP2019524723 A5 JP 2019524723A5
Authority
JP
Japan
Prior art keywords
skin
hydroxytryptamine
vortioxetine
hair
product
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019501427A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019524723A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2017/067791 external-priority patent/WO2018011382A1/en
Publication of JP2019524723A publication Critical patent/JP2019524723A/ja
Publication of JP2019524723A5 publication Critical patent/JP2019524723A5/ja
Pending legal-status Critical Current

Links

JP2019501427A 2016-07-15 2017-07-13 皮膚および/または毛の修復のための5−ヒドロキシトリプタミン1b受容体刺激剤 Pending JP2019524723A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IBPCT/IB2016/001136 2016-07-15
IB2016001136 2016-07-15
PCT/EP2017/067791 WO2018011382A1 (en) 2016-07-15 2017-07-13 5-hydroxytryptamine 1b receptor-stimulating agent for skin and/or hair repair

Publications (2)

Publication Number Publication Date
JP2019524723A JP2019524723A (ja) 2019-09-05
JP2019524723A5 true JP2019524723A5 (cg-RX-API-DMAC7.html) 2020-08-20

Family

ID=56787641

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019501427A Pending JP2019524723A (ja) 2016-07-15 2017-07-13 皮膚および/または毛の修復のための5−ヒドロキシトリプタミン1b受容体刺激剤

Country Status (10)

Country Link
US (1) US20190290641A1 (cg-RX-API-DMAC7.html)
EP (1) EP3484462B1 (cg-RX-API-DMAC7.html)
JP (1) JP2019524723A (cg-RX-API-DMAC7.html)
KR (1) KR20190038840A (cg-RX-API-DMAC7.html)
CN (1) CN110022869A (cg-RX-API-DMAC7.html)
AU (1) AU2017295038B2 (cg-RX-API-DMAC7.html)
BR (1) BR112019000706A8 (cg-RX-API-DMAC7.html)
CA (1) CA3030054A1 (cg-RX-API-DMAC7.html)
MX (1) MX386989B (cg-RX-API-DMAC7.html)
WO (1) WO2018011382A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3799873A1 (en) 2015-07-17 2021-04-07 Institut Pasteur 5-hydroxytryptamine 1b receptor-stimulating agent for use as a promoter of satellite cells self-renewal and/or differentiation
US11013830B2 (en) 2015-11-20 2021-05-25 Institut Pasteur 5-hydroxytryptamine 1B receptor-stimulating agent for enhancing in vivo engraftment potential
BR112020026099A2 (pt) * 2018-06-20 2021-03-23 Lts Lohmann Therapie-Systeme Ag sistema terapêutico transdérmico que contém asenapina
CA3158781A1 (en) * 2019-10-23 2021-04-29 Michael Wood Methods of treating the symptoms of autism spectrum disorder
CN115919860B (zh) * 2022-12-05 2023-11-10 中国药科大学 氟班色林在制备治疗雄激素脱发药物中的用途

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63203625A (ja) 1987-02-19 1988-08-23 Kao Corp 5α−リダクタ−ゼ阻害剤
FR2739553B1 (fr) 1995-10-06 1998-01-02 Oreal Utilisation d'antagonistes de la bradykinine pour stimuler ou induire la pousse des cheveux et/ou stopper leur chute
FR2758263B1 (fr) * 1997-01-16 1999-12-17 Oreal Utilisation d'un antagoniste ou d'un agoniste de serotonine specifiques respectivement du recepteur 5ht2 et 5ht1d dans une composition cosmetique ou dermatologique pour peaux sensibles et composition obtenue
FR2778558B1 (fr) 1998-05-12 2001-02-16 Oreal Utilisation d'inhibiteur de metalloproteinases pour induire et/ou stimuler la croissance des cheveux ou des poils et/ou freiner leur chute
ES2147538B1 (es) 1999-01-29 2001-04-01 Revlon Consumer Prod Corp Una locion capilar con propiedades mejoradas en su accion protectora del cabello y preventiva de su caida, y de reduccion de los efectos externos de la alopecia androgenetica y con ello de la caida del cabello.
JP3441665B2 (ja) 1999-02-04 2003-09-02 株式会社資生堂 (2−置換オキシフェニル)アルカンアミド誘導体及び養毛剤、皮膚外用剤
US20060052405A1 (en) 2000-07-19 2006-03-09 Knowles W R Hair loss prevention
FR2812192B1 (fr) 2000-07-28 2003-01-31 Oreal Utilisation d'antagonistes de recepteur des prostaglandines ep-3 comme agent cosmetique permettant d'attenuer, de diminuer ou d'arreter la chute des cheveux et des poils
ATE316387T1 (de) * 2000-09-22 2006-02-15 Perlei Medical Produkte Gmbh Verwendung von antifibrinolytika für die präparation und herstellung von tupfern, kompressen oder pflaster
ES2267945T3 (es) 2001-05-31 2007-03-16 Pfizer Products Inc. Uso medico de compuestos tiromimeticos para tratar la perdida del cabello y composiciones.
EP1435899B1 (en) 2001-09-28 2009-03-11 LG Household & Health Care Ltd. A composition for promoting hair growth
UA81749C2 (uk) * 2001-10-04 2008-02-11 Х. Луннбек А/С Фенілпіперазинові похідні як інгібітори зворотного захоплення серотоніну
US6860042B2 (en) 2002-07-19 2005-03-01 Walker-Dawson Interests, Inc. Excavation system employing a jet pump
US20070292461A1 (en) * 2003-08-04 2007-12-20 Foamix Ltd. Oleaginous pharmaceutical and cosmetic foam
ATE407724T1 (de) 2002-11-12 2008-09-15 Warner Lambert Co Methode zur stimulierung von haarwuchs auf der basis von benzopyranen
CA2511089A1 (en) 2003-01-17 2004-08-05 Warner-Lambert Company Llc Androgen receptor antagonists
ES2436524T3 (es) 2003-05-22 2014-01-02 Nerviano Medical Sciences S.R.L. Derivados de pirazolo-quinazolina, procedimiento para su preparación y su uso como inhibidores de cinasas
US20050118282A1 (en) 2003-09-16 2005-06-02 Aphios Corporation Compositions and methods for inhibiting 5-alpha reductase
AR041407A1 (es) 2003-09-26 2005-05-18 Nestor Alberto Kerner Oligonucleotidos antiandrogenos utilizables en el tratamiento de patologias dermatologicas relacionadas con el metabolismo de los androgenos, sus composiciones farmaceuticas y sus usos y metodos de tratamiento
US20060009430A1 (en) 2004-07-01 2006-01-12 Kelly Gregory J Composition for the prevention and treatment of the detrimental effects of dihydrotestosterone
MXPA06015169A (es) 2004-07-08 2007-08-21 Warner Lambert Co Moduladores de androgenos.
DE202006007482U1 (de) 2006-05-10 2006-07-20 Sentner, Thomas Leuchtmöbel
MY150647A (en) * 2006-06-16 2014-02-14 Lundbeck & Co As H 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl] piperazine as a compound with combined serotonin reuptake, 5-ht3 and 5-ht1a activity for the treatment of cognitive impairment
CN101506188B (zh) * 2006-06-22 2014-01-15 雷蒙特亚特特拉维夫大学有限公司 作为具外周系统限制活性药物的五羟色胺再摄取抑制剂
FR2903984B1 (fr) 2006-07-24 2008-10-03 Genfit Sa Derives d'imidazolones substitues, preparation et utilisations
WO2008084286A2 (en) * 2006-10-25 2008-07-17 Arterial Remodeling Technologies, S.A. Method for expansion and deployment of polymeric structures including stents
US7737149B2 (en) 2006-12-21 2010-06-15 Astrazeneca Ab N-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2H-pyrazol-3-yl]-4-(3,5-dimethylpiperazin-1-yl)benzamide and salts thereof
US20100092454A1 (en) * 2006-12-22 2010-04-15 Enrico De Vivo novel use of antidepressant compounds and related compositions
ITTO20060918A1 (it) * 2006-12-22 2008-06-23 Chiara Cesano Composizione cosmetica e farmaceutica e mezzo di coltura per la rigenerazione del tessuto cutaneo, e relativi usi
EP2490669B1 (en) * 2009-10-23 2017-01-11 Fortuderm Ltd. Triptans for the treatment of psoriasis
ES2622138T3 (es) 2010-06-23 2017-07-05 Hanmi Science Co., Ltd. Nuevos derivados de pirimidina condensados para la inhibición de la actividad tirosina quinasa
CN104736176B (zh) * 2012-08-24 2017-10-13 英特格拉斯疗法有限公司 用于增强治疗剂透皮递送的化学组合物和方法
US20160101093A1 (en) * 2013-05-21 2016-04-14 Jason B. Wynberg Methods for the treatment of premature ejaculation
US9399039B1 (en) * 2015-06-30 2016-07-26 University Of South Florida Inhibitors of the FKBP51 protein from a high-throughput drug screen and methods of use

Similar Documents

Publication Publication Date Title
JP5675650B2 (ja) 向精神薬の働きを向上させるソルビン酸、安息香酸及びその誘導体
US8911342B2 (en) Apparatus and method for pulsed electrical field treatment
ES2558701T3 (es) Tratamientos potenciados de la migraña basados en miméticos de grelina
CA2813648C (en) Combinations of serotonin receptor agonists for treatment of movement disorders
EA200600820A1 (ru) Способы лечения, модификации и устранения боли с использованием 1-оксо-2-(2,6-диоксопиперидин-3-ил)-4-метилизоиндолина
IL173028A (en) Use of rotigotine for the preparation of a medicament for the treatment of depression
DE602006021444D1 (de) Therapie zur behandlung der überaktiven blase
US20070259861A1 (en) Combination therapy with non-selective COX inhibitors to prevent COX-related gastric injuries
CO5670327A2 (es) Procedimiento para el tratamiento de trastornos de depresion y ansiedad mediante terapia de combinacion
JP2020073563A (ja) 片頭痛及び疼痛に関連する状態を処置するための方法及び組成物
CN1832734A (zh) 用于治疗抑郁症的取代的2-氨基1,2,3,4-四氢化萘
JP6634445B2 (ja) ブスピロン代謝産物の使用
AR082803A1 (es) Metodos y formulaciones para el tratamiento de la trombosis con betrixaban y un inhibidor de la glicoproteina p
JP2017536421A5 (cg-RX-API-DMAC7.html)
AU2017295038B2 (en) 5-hydroxytryptamine 1B receptor-stimulating agent for skin and/or hair repair
AR057378A1 (es) Formulaciones de diclofenac y metodos para usarlas
JP6116674B2 (ja) (1r,4r)−6’−フルオロ−N,N−ジメチル−4−フェニル−4’,9’−ジヒドロ−3’H−スピロ[シクロヘキサン−1,1’−ピラノ−[3,4,b]インドール]−4−アミンおよびプロピオン酸誘導体を含む医薬組成物
JP6116679B2 (ja) (1r,4r)−6’−フルオロ−N,N−ジメチル−4−フェニル−4’,9’−ジヒドロ−3’H−スピロ[シクロヘキサン−1,1’−ピラノ[3,4,b]インドール]−4−アミンおよび抗けいれん剤を含む医薬組成物
JP2017533956A (ja) 筋肉痛を含む病態の治療のための組合せ
JP2007505156A5 (cg-RX-API-DMAC7.html)
JP6116676B2 (ja) (1r,4r)−6’−フルオロ−N,N−ジメチル−4−フェニル−4’,9’−ジヒドロ−3’H−スピロ[シクロヘキサン−1,1’−ピラノ[3,4,b]インドール]−4−アミンおよびパラセタモールまたはプロパセタモールを含む医薬組成物
AR045423A1 (es) Combinaciones de analiticos y antidepresivos
Bug et al. Phase I/II study of BI 6727 (volasertib), an intravenous polo-like kinase-1 (Plk1) inhibitor, in patients with acute myeloid leukemia (AML): results of the dose finding for BI 6727 in combination with low-dose cytarabine
JP6116678B2 (ja) (1r,4r)−6’−フルオロ−N,N−ジメチル−4−フェニル−4’,9’−ジヒドロ−3’H−スピロ[シクロヘキサン−1,1’−ピラノ[3,4,b]インドール]−4−アミンおよびNSARを含む医薬組成物
BR0316002A (pt) Métodos de tratar ou prevenir e controlar uma doença mieloproliferativa, de reduzir ou evitar de um efeito adverso associado com a administração de um segundo agente ativo em um paciente sofrendo de uma doença mieloproliferativa e de aumentar a eficácia terapêutica de um tratamento de doença mieloproliferativa, composição farmacêutica e kit